Cartesian Therapeutics, Inc. (RNAC) Shareholders’ equity 2016–2025
Cartesian Therapeutics, Inc. (RNAC) shareholders’ equity at each fiscal year-end, per SEC filings.
-$126.2MFY2025 · since FY2016: $55.0M → -$126.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$126.2M | -1755.9% |
| FY2024 | -$6.8M | +98.5% |
| FY2023 | -$440.2M | -569.1% |
| FY2022 | $93.8M | +316.6% |
| FY2021 | $22.5M | +225.1% |
| FY2020 | -$18.0M | -314.4% |
| FY2019 | $8.4M | +255.0% |
| FY2018 | -$5.4M | -110.5% |
| FY2017 | $51.8M | -5.7% |
| FY2016 | $55.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice